Back to news

Jasper Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Globe Newswire•16/11/2026•08:00 ET
0

Key Highlights

  • ➤Q3 net loss $144.5 million, versus $18.7 million a year earlier
  • ➤Cash and equivalents $135.3 million at September 30, 2026
  • ➤Phase 2 IgAN cohort enrollment completed; interim data expected in Q4 2026
  • ➤FSGS expansion cohort opened; first patient dosing expected in Q1 2027
  • ➤Private placement generated approximately $132.0 million in gross proceeds

Expert Statements

Jeet Mahal, President and Chief Executive Officer of Jasper Therapeutics

“We have made progress advancing our development programs in recent months following our acquisition of Kira Pharmaceuticals, highlighted by the recent completion of enrollment in the first cohort of our Phase 2 renal basket study evaluating vensobafusp alfa (KP104) in patients with IgA nephropathy (IgAN).”

Jeet Mahal, President and Chief Executive Officer of Jasper Therapeutics

“In addition, we enrolled the first patient with immune complex membranoproliferative glomerulonephritis (IC-MPGN) in the renal basket study and commenced an expansion cohort in patients with focal segmental glomerulosclerosis (FSGS), with the first patient expected to be dosed in the first quarter of 2027.”

Jeet Mahal, President and Chief Executive Officer of Jasper Therapeutics

“We believe that the bifunctional ability of vensobafusp alfa to inhibit both the alternative and terminal complement pathways may provide the potential for differentiated onset and efficacy in complement driven diseases, and we look forward to presenting interim data from the IgAN cohort in the fourth quarter of 2026 and additional updates from our pipeline programs in 2027.”

REDWOOD CITY, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today reported results for the fiscal quarter ended September 30, 2026, and provided a corporate update.

“We have made progress advancing our development programs in recent months following our acquisition of Kira Pharmaceuticals, highlighted by the recent completion of enrollment in the first cohort of our Phase 2 renal basket study evaluating vensobafusp alfa (KP104) in patients with IgA nephropathy (IgAN),” said Jeet Mahal, President and Chief Executive Officer of Jasper. “In addition, we enrolled the first patient with immune complex membranoproliferative glomerulonephritis (IC-MPGN) in the renal basket study and commenced an expansion cohort in patients with focal segmental glomerulosclerosis (FSGS), with the first patient expected to be dosed in the first quarter of 2027. We believe that the bifunctional ability of vensobafusp alfa to inhibit both the alternative and terminal complement pathways may provide the potential for differentiated onset and efficacy in complement driven diseases, and we look forward to presenting interim data from the IgAN cohort in the fourth quarter of 2026 and additional updates from our pipeline programs in 2027.”

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in